Editas Medicine Inc
Abierto
SectorSanidad
2.7 2.27
Resumen
Variación precio
24h
Mínimo
2.61
Máximo
2.71
Ingresos | 6.8M -18M |
|---|---|
Ventas | 9.1M 12M |
BPA | -0.15 |
Margen de beneficios | -153.322 |
Empleados | 87 |
EBITDA | 3.9M -20M |
Próximas Ganancias | 9 nov 2026 |
|---|
Capitalización Mercado | 89M 496M |
|---|---|
Apertura anterior | 0.43 |
Cierre anterior | 2.7 |
Noticias sobre sentimiento de mercado
By Acuity
75%
25%
309 / 339 Clasificación en Healthcare
Editas Medicine Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Editas Medicine Inc previsión
Sentimiento
By Acuity
309 / 339 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Coyuntura bajista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.